RE:RE:RE:RE:RE:RE:RE:RE:Clinical Trial Size in Orphan and Rare Diseases
Hello Note and I have not attacked you in any way so not sure why this is happening. I was only quoting from the article you posted and if I made a mistake on my post then I will publically apologize. So tell me if I was wrong in stating that the approval was based on 108 patients and I do believe from what I read that this may have been a subset within the trial but I might be wrong , I do not care if it was a single arm, unrandomized study or not, all I was mentioning was that it was good to see companines taking advantage of the AA pathway but also noted the number of patients involved.